Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 135 entries
Sorted by: Best Match Show Resources per page
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.

Pharmacological research

Roskoski R.
PMID: 34921994
Pharmacol Res. 2021 Dec 15;175:106037. doi: 10.1016/j.phrs.2021.106037. Epub 2021 Dec 15.

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 68 FDA-approved therapeutic agents that target about two...

Cite
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 2021;175:106037doi: 10.1016/j.phrs.2021.106037.
Roskoski, R. (2021). Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological research, 175106037. https://doi.org/10.1016/j.phrs.2021.106037
Roskoski, Robert. "Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update." Pharmacological research vol. 175 (2021): 106037. doi: https://doi.org/10.1016/j.phrs.2021.106037
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 2021 Dec 15;175:106037. doi: 10.1016/j.phrs.2021.106037. Epub 2021 Dec 15. PMID: 34921994; PMCID: PMC8691985.
Copy Download .nbib Format: NLM
Signal-transducing adaptor protein-1 and protein-2 in hematopoiesis and diseases.

Experimental hematology

Ichii M, Oritani K, Toda J, Hosen N, Matsuda T, Kanakura Y.
PMID: 34780812
Exp Hematol. 2022 Jan;105:10-17. doi: 10.1016/j.exphem.2021.11.002. Epub 2021 Nov 12.

Inflammatory and immune signals are involved in stressed hematopoiesis under myeloablation, infection, chronic inflammation, and aging. These signals also affect malignant pathogenesis, and the dysregulated immune environment which causes the resistance to treatment. On activation, various types of protein...

Cite
Ichii M, Oritani K, Toda J, et al. Signal-transducing adaptor protein-1 and protein-2 in hematopoiesis and diseases. Exp Hematol. 2021;105:10-17doi: 10.1016/j.exphem.2021.11.002.
Ichii, M., Oritani, K., Toda, J., Hosen, N., Matsuda, T., & Kanakura, Y. (2022). Signal-transducing adaptor protein-1 and protein-2 in hematopoiesis and diseases. Experimental hematology, 10510-17. https://doi.org/10.1016/j.exphem.2021.11.002
Ichii, Michiko, et al. "Signal-transducing adaptor protein-1 and protein-2 in hematopoiesis and diseases." Experimental hematology vol. 105 (2022): 10-17. doi: https://doi.org/10.1016/j.exphem.2021.11.002
Ichii M, Oritani K, Toda J, Hosen N, Matsuda T, Kanakura Y. Signal-transducing adaptor protein-1 and protein-2 in hematopoiesis and diseases. Exp Hematol. 2022 Jan;105:10-17. doi: 10.1016/j.exphem.2021.11.002. Epub 2021 Nov 12. PMID: 34780812.
Copy Download .nbib Format: NLM
Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.

The Journal of biological chemistry

Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P, Rodiles S, Holleran J, Ardecky R, Grotegut S, Olson S, Hutchinson JH, Pasquale EB, Vuori K, Deshpande AJ, Cosford NDP, Tautz L.
PMID: 34896393
J Biol Chem. 2021 Dec 10;298(1):101477. doi: 10.1016/j.jbc.2021.101477. Epub 2021 Dec 10.

Disturbance of the dynamic balance between tyrosine phosphorylation and dephosphorylation of signaling molecules, controlled by protein tyrosine kinases and protein tyrosine phosphatases (PTPs), is known to lead to the development of cancer. While most approved targeted cancer therapies are...

Cite
Raveendra-Panickar D, Finlay D, Layng FI, et al. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem. 2021;298(1):101477doi: 10.1016/j.jbc.2021.101477.
Raveendra-Panickar, D., Finlay, D., Layng, F. I., Lambert, L. J., Celeridad, M., Zhao, M., Barbosa, K., De Backer, L. J. S., Kwong, E., Gosalia, P., Rodiles, S., Holleran, J., Ardecky, R., Grotegut, S., Olson, S., Hutchinson, J. H., Pasquale, E. B., Vuori, K., Deshpande, A. J., Cosford, N. D. P., & Tautz, L. (2021). Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. The Journal of biological chemistry, 298(1), 101477. https://doi.org/10.1016/j.jbc.2021.101477
Raveendra-Panickar, Dhanya, et al. "Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells." The Journal of biological chemistry vol. 298,1 (2021): 101477. doi: https://doi.org/10.1016/j.jbc.2021.101477
Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P, Rodiles S, Holleran J, Ardecky R, Grotegut S, Olson S, Hutchinson JH, Pasquale EB, Vuori K, Deshpande AJ, Cosford NDP, Tautz L. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem. 2021 Dec 10;298(1):101477. doi: 10.1016/j.jbc.2021.101477. Epub 2021 Dec 10. PMID: 34896393.
Copy Download .nbib Format: NLM
G-CSF, the guardian of granulopoiesis.

Seminars in immunology

Mehta HM, Corey SJ.
PMID: 34772606
Semin Immunol. 2021 Apr;54:101515. doi: 10.1016/j.smim.2021.101515. Epub 2021 Nov 10.

A considerable amount of continuous proliferation and differentiation is required to produce daily a billion new neutrophils in an adult human. Of the few cytokines and factors known to control neutrophil production, G-CSF is the guardian of granulopoiesis. G-CSF/CSF3R...

Cite
Mehta HM, Corey SJ. G-CSF, the guardian of granulopoiesis. Semin Immunol. 2021;54:101515doi: 10.1016/j.smim.2021.101515.
Mehta, H. M., & Corey, S. J. (2021). G-CSF, the guardian of granulopoiesis. Seminars in immunology, 54101515. https://doi.org/10.1016/j.smim.2021.101515
Mehta, Hrishikesh M, and Corey, Seth J. "G-CSF, the guardian of granulopoiesis." Seminars in immunology vol. 54 (2021): 101515. doi: https://doi.org/10.1016/j.smim.2021.101515
Mehta HM, Corey SJ. G-CSF, the guardian of granulopoiesis. Semin Immunol. 2021 Apr;54:101515. doi: 10.1016/j.smim.2021.101515. Epub 2021 Nov 10. PMID: 34772606.
Copy Download .nbib Format: NLM
Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.

The Journal of biological chemistry

Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P, Rodiles S, Holleran J, Ardecky R, Grotegut S, Olson S, Hutchinson JH, Pasquale EB, Vuori K, Deshpande AJ, Cosford NDP, Tautz L.
PMID: 34896393
J Biol Chem. 2021 Dec 10;298(1):101477. doi: 10.1016/j.jbc.2021.101477. Epub 2021 Dec 10.

Disturbance of the dynamic balance between tyrosine phosphorylation and dephosphorylation of signaling molecules, controlled by protein tyrosine kinases and protein tyrosine phosphatases (PTPs), is known to lead to the development of cancer. While most approved targeted cancer therapies are...

Cite
Raveendra-Panickar D, Finlay D, Layng FI, et al. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem. 2021;298(1):101477doi: 10.1016/j.jbc.2021.101477.
Raveendra-Panickar, D., Finlay, D., Layng, F. I., Lambert, L. J., Celeridad, M., Zhao, M., Barbosa, K., De Backer, L. J. S., Kwong, E., Gosalia, P., Rodiles, S., Holleran, J., Ardecky, R., Grotegut, S., Olson, S., Hutchinson, J. H., Pasquale, E. B., Vuori, K., Deshpande, A. J., Cosford, N. D. P., & Tautz, L. (2021). Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. The Journal of biological chemistry, 298(1), 101477. https://doi.org/10.1016/j.jbc.2021.101477
Raveendra-Panickar, Dhanya, et al. "Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells." The Journal of biological chemistry vol. 298,1 (2021): 101477. doi: https://doi.org/10.1016/j.jbc.2021.101477
Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P, Rodiles S, Holleran J, Ardecky R, Grotegut S, Olson S, Hutchinson JH, Pasquale EB, Vuori K, Deshpande AJ, Cosford NDP, Tautz L. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem. 2021 Dec 10;298(1):101477. doi: 10.1016/j.jbc.2021.101477. Epub 2021 Dec 10. PMID: 34896393.
Copy Download .nbib Format: NLM
Nonreceptor Protein-Tyrosine Kinases in Neutrophil Activation.

Methods (San Diego, Calif.)

Welch H, Mauran C, Maridonneau-Parini I.
PMID: 8812715
Methods. 1996 Jun;9(3):607-18. doi: 10.1006/meth.1996.0067.

Nonreceptor protein-tyrosine kinases are involved in the regulation of almost all neutrophil responses such as adhesion, chemotaxis, priming, oxidative burst, and degranulation. Here, we show that phagocytosis is also regulated by protein-tyrosine kinase activity. Using various protein-tyrosine kinase inhibitors,...

Cite
Welch H, Mauran C, Maridonneau-Parini I. Nonreceptor Protein-Tyrosine Kinases in Neutrophil Activation. Methods. 1996;9(3):607-18doi: 10.1006/meth.1996.0067.
Welch, H., Mauran, C., & Maridonneau-Parini, I. (1996). Nonreceptor Protein-Tyrosine Kinases in Neutrophil Activation. Methods (San Diego, Calif.), 9(3), 607-18. https://doi.org/10.1006/meth.1996.0067
Welch, et al. "Nonreceptor Protein-Tyrosine Kinases in Neutrophil Activation." Methods (San Diego, Calif.) vol. 9,3 (1996): 607-18. doi: https://doi.org/10.1006/meth.1996.0067
Welch H, Mauran C, Maridonneau-Parini I. Nonreceptor Protein-Tyrosine Kinases in Neutrophil Activation. Methods. 1996 Jun;9(3):607-18. doi: 10.1006/meth.1996.0067. PMID: 8812715.
Copy Download .nbib Format: NLM
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.

Circulation

Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, De Paco Matallana C, Cicero S, Greco E, Singh M, Janga D, Del Mar Gil M, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH.
PMID: 34162218
Circulation. 2021 Aug 31;144(9):670-679. doi: 10.1161/CIRCULATIONAHA.121.053963. Epub 2021 Jun 24.

BACKGROUND: Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a...

Cite
Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021;144(9):670-679doi: 10.1161/CIRCULATIONAHA.121.053963.
Döbert, M., Varouxaki, A. N., Mu, A. C., Syngelaki, A., Ciobanu, A., Akolekar, R., De Paco Matallana, C., Cicero, S., Greco, E., Singh, M., Janga, D., Del Mar Gil, M., Jani, J. C., Bartha, J. L., Maclagan, K., Wright, D., & Nicolaides, K. H. (2021). Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 144(9), 670-679. https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Döbert, Moritz, et al. "Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia." Circulation vol. 144,9 (2021): 670-679. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, De Paco Matallana C, Cicero S, Greco E, Singh M, Janga D, Del Mar Gil M, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021 Aug 31;144(9):670-679. doi: 10.1161/CIRCULATIONAHA.121.053963. Epub 2021 Jun 24. PMID: 34162218.
Copy Download .nbib Format: NLM
Protein Tyrosine Phosphatases: Mechanisms in Cancer.

International journal of molecular sciences

Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T, Peethambaran B.
PMID: 34884670
Int J Mol Sci. 2021 Nov 28;22(23). doi: 10.3390/ijms222312865.

Protein tyrosine kinases, especially receptor tyrosine kinases, have dominated the cancer therapeutics sphere as proteins that can be inhibited to selectively target cancer. However, protein tyrosine phosphatases (PTPs) are also an emerging target. Though historically known as negative regulators...

Cite
Sivaganesh V, Sivaganesh V, Scanlon C, et al. Protein Tyrosine Phosphatases: Mechanisms in Cancer. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222312865.
Sivaganesh, V., Sivaganesh, V., Scanlon, C., Iskander, A., Maher, S., Lê, T., & Peethambaran, B. (2021). Protein Tyrosine Phosphatases: Mechanisms in Cancer. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222312865
Sivaganesh, Vignesh, et al. "Protein Tyrosine Phosphatases: Mechanisms in Cancer." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222312865
Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T, Peethambaran B. Protein Tyrosine Phosphatases: Mechanisms in Cancer. Int J Mol Sci. 2021 Nov 28;22(23). doi: 10.3390/ijms222312865. PMID: 34884670.
Copy Download .nbib Format: NLM
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.

Pharmacological research

Roskoski R.
PMID: 33513356
Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26.

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the protein kinase enzyme family has become one of the most important drug targets in the 21st century. There are 62 FDA-approved therapeutic agents that target...

Cite
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol Res. 2021;165:105463doi: 10.1016/j.phrs.2021.105463.
Roskoski, R. (2021). Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological research, 165105463. https://doi.org/10.1016/j.phrs.2021.105463
Roskoski, Robert. "Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update." Pharmacological research vol. 165 (2021): 105463. doi: https://doi.org/10.1016/j.phrs.2021.105463
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26. PMID: 33513356.
Copy Download .nbib Format: NLM
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives.

Seminars in cancer biology

Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, Vikkurthi R, Devi TB, Gupta SC, Kunnumakkara AB.
PMID: 32610149
Semin Cancer Biol. 2020 Jun 28; doi: 10.1016/j.semcancer.2020.06.014. Epub 2020 Jun 28.

Despite significant advancements made in the treatment of cancer during the past several decades, it remains one of the leading causes of death worldwide killing approximately 9.6 million people annually. The major challenge for therapeutic success is the development...

Cite
Khatoon E, Banik K, Harsha C, et al. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin Cancer Biol. 2020;doi: 10.1016/j.semcancer.2020.06.014.
Khatoon, E., Banik, K., Harsha, C., Sailo, B. L., Thakur, K. K., Khwairakpam, A. D., Vikkurthi, R., Devi, T. B., Gupta, S. C., & Kunnumakkara, A. B. (2020). Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Seminars in cancer biology, . https://doi.org/10.1016/j.semcancer.2020.06.014
Khatoon, Elina, et al. "Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives." Seminars in cancer biology vol. (2020). doi: https://doi.org/10.1016/j.semcancer.2020.06.014
Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, Vikkurthi R, Devi TB, Gupta SC, Kunnumakkara AB. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin Cancer Biol. 2020 Jun 28; doi: 10.1016/j.semcancer.2020.06.014. Epub 2020 Jun 28. PMID: 32610149.
Copy Download .nbib Format: NLM
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.

Nature reviews. Clinical oncology

Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A.
PMID: 34561632
Nat Rev Clin Oncol. 2021 Sep 24; doi: 10.1038/s41571-021-00558-1. Epub 2021 Sep 24.

Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast and gastroesophageal cancers, and are of relevance for the treatment of various other malignancies...

Cite
Friedlaender A, Subbiah V, Russo A, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2021;doi: 10.1038/s41571-021-00558-1.
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C., & Addeo, A. (2021). EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature reviews. Clinical oncology, . https://doi.org/10.1038/s41571-021-00558-1
Friedlaender, Alex, et al. "EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment." Nature reviews. Clinical oncology vol. (2021). doi: https://doi.org/10.1038/s41571-021-00558-1
Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2021 Sep 24; doi: 10.1038/s41571-021-00558-1. Epub 2021 Sep 24. PMID: 34561632.
Copy Download .nbib Format: NLM
G-CSF, the guardian of granulopoiesis.

Seminars in immunology

Mehta HM, Corey SJ.
PMID: 34772606
Semin Immunol. 2021 Nov 09;101515. doi: 10.1016/j.smim.2021.101515. Epub 2021 Nov 09.

A considerable amount of continuous proliferation and differentiation is required to produce daily a billion new neutrophils in an adult human. Of the few cytokines and factors known to control neutrophil production, G-CSF is the guardian of granulopoiesis. G-CSF/CSF3R...

Cite
Mehta HM, Corey SJ. G-CSF, the guardian of granulopoiesis. Semin Immunol. 2021;101515doi: 10.1016/j.smim.2021.101515.
Mehta, H. M., & Corey, S. J. (2021). G-CSF, the guardian of granulopoiesis. Seminars in immunology, 101515. https://doi.org/10.1016/j.smim.2021.101515
Mehta, Hrishikesh M, and Corey, Seth J. "G-CSF, the guardian of granulopoiesis." Seminars in immunology vol. (2021): 101515. doi: https://doi.org/10.1016/j.smim.2021.101515
Mehta HM, Corey SJ. G-CSF, the guardian of granulopoiesis. Semin Immunol. 2021 Nov 09;101515. doi: 10.1016/j.smim.2021.101515. Epub 2021 Nov 09. PMID: 34772606.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 135 entries